BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced that data about hypoparathyroidism will be presented at the 2011 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego, CA, September 16-20, 2011. NPSP558, the company’s bioengineered replica of human parathyroid hormone (rhPTH 1-84), is currently in development as the first hormone replacement therapy for hypoparathyroidism. The presentations will include findings from investigator-initiated studies of rhPTH (1-84) and new information about the costs and co-morbidities associated with hypoparathyroidism.
